Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout Opportunity
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is highlighted as a high-growth company with a promising technical breakout opportunity. The biopharmaceutical firm boasts exceptional revenue and earnings growth, supported by a strong RNAi platform and strategic partnerships. After a significant rise, the stock is currently in a consolidation phase near a key resistance point, suggesting a potential restart of its upward trend.
Aberdeen Group plc Sells 439,601 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
Aberdeen Group plc has reduced its stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by 45.8% during the third quarter, selling 439,601 shares and now holding 520,644 shares valued at $17.96 million. Despite this sale, analysts maintain a "Moderate Buy" consensus rating with an average target price of $81.67, following several price target lifts to around the $80 range. The company reported strong revenue growth of 10,461% year-over-year in its latest quarter but missed EPS estimates, leading to projected negative full-year EPS.
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited
Morgan Stanley has lowered its price target for Arrowhead Pharmaceuticals (ARWR) to $78 from $81, maintaining an Equal Weight rating. The firm anticipates that significant sales from their familial chylomicronemia syndrome treatment will not materialize until 2026, despite promising early launch trends. Arrowhead Pharmaceuticals is also advancing its pipeline, including a new Phase 1/2a clinical trial for ARO-DIMER-PA, an RNAi therapy for atherosclerotic cardiovascular disease.
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited
Morgan Stanley has lowered its price target for Arrowhead Pharmaceuticals (ARWR) to $78 from $81, maintaining an Equal Weight rating, according to TheFly. Despite promising early launch trends for its familial chylomicronemia syndrome treatment, the firm anticipates that significant sales from this program will not materialize in 2026. Separately, Arrowhead Pharmaceuticals has begun a Phase 1/2a clinical trial for ARO-DIMER-PA, an investigational RNAi therapy targeting atherosclerotic cardiovascular disease by suppressing APOC3 and PCSK9 genes.
Public Sector Pension Investment Board Grows Position in Arrowhead Pharmaceuticals, Inc. $ARWR
The Public Sector Pension Investment Board increased its stake in Arrowhead Pharmaceuticals, Inc. by 25.9% in Q3, now owning 539,336 shares valued at $18.6 million. This comes as multiple analysts have raised price targets for ARWR, resulting in a "Moderate Buy" consensus and an average target of $81.67. Despite missing EPS estimates, Arrowhead Pharmaceuticals reported strong revenue growth, significantly beating expectations.
AlphaQuest LLC Sells 30,501 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
AlphaQuest LLC significantly reduced its stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by 93.6% in Q3, selling 30,501 shares. Despite this, institutional investors like Marshall Wace LLP, Norges Bank, and Invesco Ltd. increased their holdings, and analysts maintain a "Moderate Buy" rating with a target price of $81.67, driven by positive commercialization news for REDEMPLO and multiple price target raises. The company recently missed EPS expectations but beat revenue forecasts for the quarter.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Arrowhead Pharmaceuticals (NASDAQ:ARWR) has received a "Moderate Buy" consensus rating from eleven analysts, with an average 12-month price target of $81.67. The company recently reported mixed quarterly results, beating revenue expectations but missing on EPS, and management highlighted a strong start to REDEMPLO commercialization. While institutional ownership is significant, insiders have recently sold shares.
Arrowhead Pharmaceuticals (ARWR) Valuation Check After Earnings Jump And S&P Index Move
Arrowhead Pharmaceuticals (ARWR) has gained attention due to reporting first-quarter profitability and a shift from the S&P 600 to the S&P 400 indices. Despite a 220% one-year total shareholder return, its current valuation is debated. While a narrative fair value of $64.08 suggests it's undervalued, its P/E ratio of 44.2x is seen as rich, indicating potential valuation risk if expectations for its RNAi pipeline cool.
Is Arrowhead’s Profit Surge and S&P MidCap 400 Move Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?
Arrowhead Pharmaceuticals reported a significant profit surge in Q1 2026, with sales of US$264.03 million and net income of US$30.81 million, a substantial improvement from a loss a year prior. The company also moved from the S&P SmallCap 600 to the S&P MidCap 400, reflecting its growth. While these developments are positive, the article emphasizes that the investment case still hinges on clinical trial outcomes, competitive pressures, and partner-dependent revenue for its RNAi platform and cardiometabolic assets.
Is Arrowhead’s Profit Surge and S&P MidCap 400 Move Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?
Arrowhead Pharmaceuticals reported a significant first-quarter 2026 profit of US$30.81 million, a substantial increase from a loss in the prior year, alongside sales of US$264.03 million. The company was also reclassified into the S&P MidCap 400. While these developments are positive, the article emphasizes that the investment narrative still involves execution risks from late-stage trials, competitive pressures, and partner-dependent revenues.
Zacks Research Issues Negative Estimate for ARWR Earnings
Zacks Research has lowered its Q2 2026 EPS estimate for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to ($1.29) from ($1.14), forecasting a full-year 2026 loss of ($4.11), significantly below the consensus. This follows Arrowhead's recent earnings report, which missed EPS expectations but beat revenue estimates with a substantial year-over-year increase. Despite the negative estimate revision, analyst sentiment generally remains positive, with a consensus rating of "Moderate Buy" and an average price target of $81.67.
Johnson Investment Counsel Inc. Makes New $781,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR
Johnson Investment Counsel Inc. has initiated a new $781,000 investment in Arrowhead Pharmaceuticals (NASDAQ:ARWR), purchasing 22,635 shares in the third quarter. This comes amidst significant insider selling, with company executives selling over $33.6 million worth of shares recently. Despite insider sales, analysts have assigned a consensus "Moderate Buy" rating with an $81.67 price target, reflecting continued positive sentiment for the biotechnology company.
Equities Analysts Issue Forecasts for ARWR Q2 Earnings
HC Wainwright analysts have adjusted their Q2 2026 EPS estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to ($0.98), a slight decrease from their previous forecast. Despite this, HC Wainwright maintains a "Buy" rating and a $100.00 price target on the stock, while other firms like Royal Bank Of Canada and Bank of America have also issued "outperform" or "buy" ratings with increased price targets. The company's stock has seen significant institutional investment, though some insider selling has also occurred recently.
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality
Despite reporting decent profit numbers, investors were disappointed with Arrowhead Pharmaceuticals' recent earnings announcement. However, further analysis of the company's financials, particularly its strong free cash flow relative to earnings (indicated by a negative accrual ratio), suggests the earnings are of good quality. The primary concern is share dilution, which is causing earnings per share to drop faster than net profit.
The Strong Earnings Posted By Arrowhead Pharmaceuticals (NASDAQ:ARWR) Are A Good Indication Of The Strength Of The Business
Arrowhead Pharmaceuticals (NASDAQ:ARWR) posted strong earnings, yet investors seemed underwhelmed. The analysis suggests optimism is warranted as the strong profit is built on solid foundations, indicated by a negative accrual ratio. However, dilution from new share issuance is impacting earnings per share, despite the company returning to profitability.
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality
Arrowhead Pharmaceuticals reported strong earnings that, despite initial investor disappointment, were of good quality due to a negative accrual ratio indicating high free cash flow generation. However, significant share dilution from new stock issuance has negatively impacted earnings per share, raising concerns about per-share returns despite overall profit growth.
Arrowhead Joins S&P 400 As Profitability Shifts Investor Focus
Arrowhead Pharmaceuticals (NasdaqGS:ARWR) has moved from the S&P 600 to the S&P 400 index, signifying its reclassification as a mid-cap company. This reclassification coincides with the company's recent achievement of profitability, reporting Q1 sales of US$264.03 million and net income of US$30.81 million. The change could increase investment attention and liquidity for Arrowhead, though risks related to clinical trial outcomes and market volatility remain.
Principal Financial Group Inc. Buys 157,035 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
Principal Financial Group Inc. significantly increased its stake in Arrowhead Pharmaceuticals, Inc. by 25.2%, acquiring an additional 157,035 shares, bringing their total to 780,132 shares valued at approximately $26.9 million. This transaction occurred despite recent insider selling by executives like James C. Hamilton and CEO Christopher Anzalone. While Arrowhead missed quarterly EPS expectations, it reported a substantial revenue beat and year-over-year growth, leading to a "Moderate Buy" consensus rating from analysts with an average target price of $81.67.
Arrowhead Joins S&P 400 As Profitability Shifts Investor Focus
Arrowhead Pharmaceuticals (NasdaqGS:ARWR) has been added to the S&P 400 index, moving from the S&P 600, reflecting its reclassification as a mid-cap company. This shift coincides with a significant improvement in the company's financial performance, reporting Q1 sales of US$264.03 million and a net income of US$30.81 million after a previous loss. The index inclusion and profitability signal a progression for Arrowhead, though risks related to trial outcomes and market volatility remain.
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright has reiterated a "Buy" rating for Arrowhead Pharmaceuticals (ARWR), setting a price target of $100, which suggests a 59.85% upside. Despite a significant revenue beat in the latest quarter with revenue up over 10,000% year-over-year, the company missed EPS estimates. Insiders have sold a substantial number of shares recently, though institutional ownership remains high at about 62.6%.
Goldman Sachs Maintains Neutral on ARWR Arrowhead Pharmaceuticals Feb 2026
Goldman Sachs has maintained a "Neutral" rating on Arrowhead Pharmaceuticals (ARWR) as of February 9, 2026, without issuing a new price target. The firm is awaiting clearer commercial and clinical progress for the company's REDEMPLO and pipeline. For investors, this rating suggests a hold stance, emphasizing monitoring upcoming commercial uptake and clinical readouts.
ARROWHEAD PHARMACEUTICALS, INC. SEC 10-Q Report
Arrowhead Pharmaceuticals, Inc. (ARWR) has released its latest Form 10-Q report, demonstrating significant financial and operational improvements. The company reported substantial revenue growth and profitability driven by strategic collaborations and pipeline developments, including milestone payments from Sarepta and Novartis, and the FDA approval of REDEMPLO®. Arrowhead's robust pipeline, manufacturing facility expansion, and international market presence signal a positive future outlook.
Arrowhead Pharmaceuticals (ARWR) Q1 Profit Challenges Bearish Narratives On Earnings Quality
Arrowhead Pharmaceuticals (ARWR) reported strong Q1 2026 results with US$264.0 million in revenue and US$0.22 basic EPS, demonstrating a shift to profitability after previous losses. The company's trailing twelve-month net income reached US$202.3 million on US$1.09 billion revenue. Despite a high P/E ratio of 44.7x compared to peers and modest earnings growth forecasts, the positive earnings inflection and a DCF fair value of US$144.20 suggest a potentially undervalued stock according to some analyses.
Arrowhead Pharmaceuticals (ARWR) Q1 Profit Challenges Bearish Narratives On Earnings Quality
Arrowhead Pharmaceuticals (ARWR) reported strong Q1 2026 results with US$264.0 million in revenue and US$0.22 EPS, continuing its shift to profitability. This performance challenges bearish views on earnings quality, despite the company's P/E ratio being significantly higher than peers and modest growth forecasts. The article also highlights a DCF fair value suggesting the stock is undervalued, leading to a nuanced investment consideration.
Arrowhead gains approval of Redemplo in China for high triglycerides
Arrowhead Pharmaceuticals has received approval from China's National Medical Products Administration for its investigational new drug application for Redemplo (ARO-APOC3). This approval allows Arrowhead to initiate a Phase 3 clinical trial in China for patients with severe hypertriglyceridemia, a condition characterized by very high levels of triglycerides. Redemplo is an RNA interference therapeutic designed to reduce APOC3, a protein that plays a key role in triglyceride metabolism.
Arrowhead’s RNAi Platform Shifts Toward Commercialization And Broader Partnerships
Arrowhead Pharmaceuticals has achieved a significant milestone by receiving FDA approval for REDEMPLO, launching its first commercial product, and establishing a global partnership with Novartis for an RNAi therapy. These developments signal a strategic shift from a pure development focus toward commercialization and broader collaborations for its RNA interference platform. Investors should monitor REDEMPLO's commercial progress, the Novartis partnership's evolution, and early data from ARO DIMER PA, as these factors will shape the market's perception of Arrowhead's long-term potential.
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
Arrowhead Pharmaceuticals announced strong financial results for its fiscal 2026 first quarter, reporting significant progress across its business. Key achievements include the regulatory approval and U.S. launch of REDEMPLO® for familial chylomicronemia syndrome, advancements in cardiometabolic and obesity programs, and a strengthened financial position through successful public offerings and milestone payments. The company also highlighted positive clinical data from its RNAi-based obesity candidates and the initiation of new trials for neurological conditions.
Arrowhead’s RNAi Platform Shifts Toward Commercialization And Broader Partnerships
Arrowhead Pharmaceuticals has achieved a significant milestone by receiving FDA approval for REDEMPLO, launching its first commercial product, and establishing a global partnership with Novartis for an RNAi therapy in synucleinopathies. Additionally, the company initiated a Phase 1/2a trial for ARO DIMER PA, a dual-target RNAi therapeutic for cardiovascular disease. These developments signify a strategic shift towards commercialization and broader application of its RNAi platform, moving beyond a pure development focus.
Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M
Arrowhead Pharmaceuticals, Inc. (ARWR) announced its Q1 revenue reached $264.0 million, significantly surpassing FactSet's estimate of $213.9 million. The company specializes in developing RNAi-based therapies for intractable diseases, with its TRiM™ platform enabling tissue-specific targeting. Arrowhead has 14 clinical-stage investigational medicines, including wholly owned and partnered assets.
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
Arrowhead Pharmaceuticals announced strong financial results for its fiscal 2026 first quarter, ended December 31, 2025, highlighted by the regulatory approval and U.S. launch of REDEMPLO® for familial chylomicronemia syndrome. The company also reported significant R&D advancements, including early encouraging results from obesity programs and initiation of new clinical trials, alongside strategic corporate events that improved its financial position. Christopher Anzalone, Ph.D., President and CEO, emphasized the company's strong execution and position for future growth.
Arrowhead (ARWR) Set to Join S&P 400 Index
Arrowhead Pharmaceuticals Inc. (ARWR) is slated to join the S&P 400 index on February 9th, replacing Ciena Corporation, a move expected to boost its visibility and attract more investors. The biotechnology company, with a market cap of around $9.53 billion, focuses on genetic disease treatments and exhibits strong revenue growth despite current profitability challenges. While the company shows financial strength and low bankruptcy risk, investors should note its high stock volatility and the warning sign of potential financial manipulation indicated by its Beneish M-Score and recent insider selling.
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
Ciena Corp. will replace Dayforce Inc. in the S&P 500, Arrowhead Pharmaceuticals Inc. will join the S&P MidCap 400, and ADT Inc. will replace Arrowhead in the S&P SmallCap 600, effective February 9, 2026. OneSpaWorld Holdings Ltd. will also join the S&P SmallCap 600, replacing Dynavax Technologies Corp., effective February 10, 2026. These changes are due to acquisitions of Dayforce by Thoma Bravo L.P. and Dynavax Technologies by Sanofi.
Is Arrowhead Pharmaceuticals (ARWR) Pricing Reflect Recent RNAi Progress And Strong Share Price Gains?
This article analyzes Arrowhead Pharmaceuticals (ARWR) through two valuation methods: Discounted Cash Flow (DCF) and Price/Sales (P/S). The DCF analysis suggests the stock is significantly undervalued by 47.3%, projecting a fair value of US$136.94 per share. However, the P/S ratio indicates the stock is currently overvalued compared to its fair ratio, albeit close to the industry average.
Is Arrowhead Pharmaceuticals (ARWR) Pricing Reflect Recent RNAi Progress And Strong Share Price Gains?
Arrowhead Pharmaceuticals (ARWR) has seen significant share price gains, with recent coverage highlighting its RNA interference therapy progress. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 47.3% at US$72.14, with an estimated intrinsic value of US$136.94 per share. However, its Price-to-Sales (P/S) ratio of 12.18x, compared to a Fair Ratio of 9.90x, indicates it might be overvalued by that measure.
Arrowhead Pharmaceuticals (ARWR) Valuation After First Human Dosing Of Dual Gene RNAi Therapy For Mixed Hyperlipidemia
Arrowhead Pharmaceuticals has initiated a Phase 1/2a trial for ARO DIMER PA, an RNAi therapy targeting mixed hyperlipidemia. The company's shares have seen significant recent gains, with a 90-day return of 92.87% and a one-year return of 289.54%. While one valuation narrative suggests ARWR is 13.9% overvalued with a fair value of $64, a discounted cash flow model points to a fair value of $140.19, indicating potential undervaluation.
Arrowhead Pharmaceuticals (ARWR) Valuation After First Human Dosing Of Dual Gene RNAi Therapy For Mixed Hyperlipidemia
Arrowhead Pharmaceuticals has initiated a Phase 1/2a trial for ARO DIMER PA, an RNAi therapy for mixed hyperlipidemia, following a period of strong stock performance. While the company's shares have seen significant returns, current valuations suggest conflicting views: one narrative sees it 13.9% overvalued at $64, while a DCF model indicates a fair value of $140.19, significantly higher than its current trading price of $73. Investors are encouraged to consider these different valuation perspectives and potential risks.
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following First Dual-Gene RNAi Cardio Trial Initiation
Arrowhead Pharmaceuticals has initiated a Phase 1/2a trial for ARO-DIMER-PA, an RNAi therapeutic designed to silence two genes (PCSK9 and APOC3) simultaneously for atherosclerotic cardiovascular disease. This first-in-human dual-gene RNAi trial marks a significant advance in treating cardiovascular risk and could shape the company's long-term investment narrative by showcasing the versatility of its TRiM platform. While near-term catalysts remain focused on pipeline readouts and partnerships, the dual-gene approach highlights potential for differentiated cardiometabolic drugs.
The Technical Signals Behind (ARWR) That Institutions Follow
This article analyzes Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) through technical signals that institutions follow, identifying strong sentiment across all horizons and an overweight bias. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss points. The analysis also provides multi-timeframe signal insights, including support and resistance levels for near-term, mid-term, and long-term horizons, indicating strong signals across the board.
Arrowhead Pharmaceuticals, Inc. $ARWR is Privium Fund Management B.V.'s 9th Largest Position
Privium Fund Management B.V. has reduced its stake in Arrowhead Pharmaceuticals (ARWR) by 22.6%, making it their 9th largest holding. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $81.67. Insider selling of 510,836 shares worth $33.6 million has occurred in the past 90 days, while institutional investors hold 62.61% of the company's stock.
Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Thursday
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is scheduled to release its Q1 2026 earnings after market close on Thursday, February 5th, with analysts forecasting EPS of $0.82 and revenue of $225.658 million. The company has recently seen positive analyst momentum, with multiple brokers raising price targets, and a consensus "Moderate Buy" rating with an average target price of $81.67. Insider selling has been notable, with COO Patrick O'Brien and Director Mauro Ferrari recently selling shares, though insiders still own 4.30% of the company.
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals has started a Phase 1/2a clinical trial for ARO-DIMER-PA, its innovative RNAi therapeutic designed to treat mixed hyperlipidemia. This therapeutic is notable for being the first clinical candidate capable of simultaneously silencing two genes, PCSK9 and APOC3, using a single RNAi molecule, leveraging Arrowhead's proprietary TRiM™ platform. The study aims to evaluate ARO-DIMER-PA's safety, tolerability, pharmacokinetics, and its effects on LDL-C and triglycerides in adults with mixed hyperlipidemia, addressing a significant risk factor for atherosclerotic cardiovascular disease.
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals has initiated a Phase 1/2a clinical trial for ARO-DIMER-PA, a first-of-its-kind dual functional RNAi therapeutic aimed at treating mixed hyperlipidemia, a significant risk factor for atherosclerotic cardiovascular disease. Enabled by Arrowhead's proprietary TRiM™ platform, ARO-DIMER-PA is designed to simultaneously silence two genes, PCSK9 and APOC3, offering a novel approach to reduce LDL-cholesterol and triglycerides. This development expands Arrowhead's cardiometabolic portfolio and highlights its leadership in RNAi therapeutics.
Arrowhead Pharma stock holds steady as Morgan Stanley maintains rating
Morgan Stanley has maintained its Equalweight rating and an $81.00 price target for Arrowhead Pharmaceuticals, citing encouraging progress in its ARO-DIMER-PA program. While ARO-DIMER-PA data is expected in H2 2026, the key catalyst for 2026 is seen to be the Phase 3 SHASTA-3/4 studies of Redemplo, with topline data anticipated in Q3 2026. The stock has seen a significant 324% return in the past six months, although InvestingPro data suggests it may be overvalued relative to analyst targets ranging from $35 to $110.
160,985 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH recently acquired a new stake of 160,985 shares in Arrowhead Pharmaceuticals (NASDAQ:ARWR), valued at approximately $5.55 million, during the third quarter. This acquisition represents about 0.12% of the biotechnology company, according to a 13F filing. Despite significant insider selling totaling some $33.6 million in the last 90 days, analysts maintain a consensus "Moderate Buy" rating for ARWR with an average price target of $81.67.
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals has initiated a Phase 1/2a clinical trial for ARO-DIMER-PA, a first-of-its-kind dual functional RNAi therapeutic aimed at treating mixed hyperlipidemia. This investigational drug is designed to simultaneously silence two genes, PCSK9 and APOC3, which are key targets for reducing LDL-cholesterol and triglycerides. The study highlights the versatility of Arrowhead’s proprietary TRiM™ technology and its potential to address atherosclerotic cardiovascular disease.
Arrowhead Pharmaceuticals (ARWR) Valuation Check After Redemplo’s Third Regulatory Approval And Optimistic Pipeline Outlook
Arrowhead Pharmaceuticals' drug Redemplo secured its third regulatory approval in China, following clearances in the US and Canada, leading to fresh investor interest and significant share price returns. Despite a "most popular narrative" suggesting the stock is slightly overvalued at $67.05 with a fair value of $64.08, a discounted cash flow (DCF) model indicates the shares might be trading at a 53% discount to an estimated future cash flow value of $141.37. The company's advancing late-stage pipeline, including plozasiran, is expected to accelerate revenue growth as approvals and launches materialize.
Arrowhead Pharmaceuticals (ARWR) Is Up 5.0% After China Approves Redemplo Commercialisation With Sanofi
Arrowhead Pharmaceuticals (ARWR) shares rose after China's National Medical Products Administration approved Redemplo (plozasiran) for familial chylomicronemia syndrome, with Sanofi leading commercialization in Greater China. This approval expands Arrowhead's global RNA interference footprint and provides an early commercial test ahead of a potential US decision in 2025. Investors are still weighing risks like continued losses, equity dilution, and volatile sentiment, but the China approval adds incremental validation.
Arrowhead Pharmaceuticals (ARWR) Is Up 5.0% After China Approves Redemplo Commercialisation With Sanofi
Arrowhead Pharmaceuticals saw its stock rise 5.0% after China's National Medical Products Administration approved Redemplo (plozasiran) for familial chylomicronemia syndrome, with Sanofi handling commercialization in Greater China. This approval expands Arrowhead's global reach and offers early insights into commercial execution, though the primary near-term catalyst remains a potential US decision on plozasiran in 2025. Investors are still weighing risks like continued losses, equity dilution, rich sales multiples, and volatile sentiment against the strengthening investment narrative.
Is Arrowhead Pharmaceuticals (ARWR) Fairly Priced After Strong 1 Year Share Price Surge?
Arrowhead Pharmaceuticals (ARWR) has experienced a significant 243.0% gain over the last year, prompting a valuation analysis. Based on a Discounted Cash Flow (DCF) model, the stock appears 51.8% undervalued with an intrinsic value of $140.39 per share compared to its current price of $67.60. However, its Price/Sales (P/S) ratio of 11.20x is above Simply Wall St's Fair Ratio of 9.63x, suggesting it could be overvalued on this metric.
Is Arrowhead Pharmaceuticals (ARWR) Fairly Priced After Strong 1 Year Share Price Surge?
Arrowhead Pharmaceuticals (ARWR) has seen a significant 243% gain over the last year, prompting a valuation analysis. A Discounted Cash Flow (DCF) model suggests the stock is 51.8% undervalued at $140.39 compared to its current price of $67.60. However, its Price to Sales (P/S) ratio of 11.20x is above Simply Wall St's "Fair Ratio" of 9.63x, indicating it might be overvalued by this metric.
